Paper42935367PubMed
An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.
Childs S and 15 others. Med J Aust, 2026.
Cite this record
ConductScience Library. An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres. Papers, record 42935367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42935367
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres.
- Journal
- Med J Aust
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-29
Source PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Humans | |
| Australia | |
| Referral and Consultation |
Source PubMed
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33979178 | Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33979178 | PubMed |
| 2 | 40378343 | Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis. | Blood Adv | 2025 | https://conductscience.org/library/papers/40378343 | PubMed |
| 3 | 36717905 | CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. | Mol Cancer | 2023 | https://conductscience.org/library/papers/36717905 | PubMed |
| 4 | 37420216 | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. | J Transl Med | 2023 | https://conductscience.org/library/papers/37420216 | PubMed |
| 5 | 30518633 | A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30518633 | PubMed |
| 6 | 38683966 | HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. | Blood | 2024 | https://conductscience.org/library/papers/38683966 | PubMed |
| 7 | 40089329 | Tumor-Infiltrating Lymphocyte Therapy: A New Frontier. | Transplant Cell Ther | 2025 | https://conductscience.org/library/papers/40089329 | PubMed |
| 8 | 37872225 | CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37872225 | PubMed |
| 9 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 10 | 34279805 | Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care. | Adv Ther | 2021 | https://conductscience.org/library/papers/34279805 | PubMed |
| 11 | 39603960 | Advances in cell therapy: progress and challenges in hematological and solid tumors. | Trends Pharmacol Sci | 2024 | https://conductscience.org/library/papers/39603960 | PubMed |
| 12 | 41543441 | Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries. | Blood | 2026 | https://conductscience.org/library/papers/41543441 | PubMed |
| 13 | 39697210 | The current socioeconomic and regulatory landscape of immune effector cell therapies. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39697210 | PubMed |
| 14 | 41530803 | The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis. | Eur J Med Res | 2026 | https://conductscience.org/library/papers/41530803 | PubMed |
| 15 | 39837618 | Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/39837618 | PubMed |
| 16 | 3264384 | Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. | N Engl J Med | 1988 | https://conductscience.org/library/papers/3264384 | PubMed |
| 17 | 31921205 | The Intriguing History of Cancer Immunotherapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31921205 | PubMed |
| 18 | 21282551 | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21282551 | PubMed |
| 19 | 36604431 | Neoantigens: promising targets for cancer therapy. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36604431 | PubMed |
| 20 | 36906275 | Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. | Transplant Cell Ther | 2023 | https://conductscience.org/library/papers/36906275 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42935367
GET https://conductscience.org/api/papers/v1/42935367/references?page=2